ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Abstract

NK-92 cells, and their derivative, designated aNK, were obtained from a patient with non-Hodgkin lymphoma. Prior clinical studies employing adoptively transferred irradiated aNK cells have provided evidence of clinical benefit and an acceptable safety profile. aNK cells have now been engineered to express IL-2 and the high affinity (ha) CD16 allele… (More)
DOI: 10.1002/ijc.30767

Topics

Cite this paper

@article{Jochms2017ADCCEA, title={ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.}, author={Caroline Joch{\'e}ms and James W. Hodge and Massimo Claudio Fantini and Kwong Yok Tsang and Amanda J. Vandeveer and James L. Gulley and Jeffrey Schlom}, journal={International journal of cancer}, year={2017}, volume={141 3}, pages={583-593} }